Niagen Bioscience Inc (NASDAQ: NAGE) kicked off on Friday, up 4.29% from the previous trading day, before settling in for the closing price of $10.50. Over the past 52 weeks, NAGE has traded in a range of $2.31-$10.68.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 16.76% over the past five years. While this was happening, its average annual earnings per share was recorded 29.23%. With a float of $49.81 million, this company’s outstanding shares have now reached $78.43 million.
Let’s look at the performance matrix of the company that is accounted for 104 employees. In terms of profitability, gross margin is 62.51%, operating margin of 12.26%, and the pretax margin is 13.51%.
Niagen Bioscience Inc (NAGE) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Niagen Bioscience Inc is 36.86%, while institutional ownership is 31.80%. The most recent insider transaction that took place on Mar 07 ’25, was worth 2,146. In this transaction SVP, General Counsel of this company bought 273 shares at a rate of $7.86, taking the stock ownership to the 2,251 shares. Before that another transaction happened on Dec 13 ’24, when Company’s Director sold 37,161 for $6.19, making the entire transaction worth $229,956. This insider now owns 244,179 shares in total.
Niagen Bioscience Inc (NAGE) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 29.23% per share during the next fiscal year.
Niagen Bioscience Inc (NASDAQ: NAGE) Trading Performance Indicators
Take a look at Niagen Bioscience Inc’s (NAGE) current performance indicators. Last quarter, stock had a quick ratio of 3.12. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.99. Likewise, its price to free cash flow for the trailing twelve months is 44.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.17, a number that is poised to hit 0.02 in the next quarter and is forecasted to reach 0.23 in one year’s time.
Technical Analysis of Niagen Bioscience Inc (NAGE)
Niagen Bioscience Inc (NASDAQ: NAGE) saw its 5-day average volume 1.2 million, a positive change from its year-to-date volume of 0.84 million. As of the previous 9 days, the stock’s Stochastic %D was 96.21%. Additionally, its Average True Range was 0.55.
During the past 100 days, Niagen Bioscience Inc’s (NAGE) raw stochastic average was set at 99.40%, which indicates a significant increase from 99.01% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.66% in the past 14 days, which was lower than the 88.25% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.59, while its 200-day Moving Average is $5.60. Nevertheless, the first resistance level for the watch stands at $11.16 in the near term. At $11.38, the stock is likely to face the second major resistance level. The third major resistance level sits at $11.77. If the price goes on to break the first support level at $10.56, it is likely to go to the next support level at $10.16. The third support level lies at $9.95 if the price breaches the second support level.
Niagen Bioscience Inc (NASDAQ: NAGE) Key Stats
The company with the Market Capitalisation of 862.53 million has total of 78,770K Shares Outstanding. Its annual sales at the moment are 99,600 K in contrast with the sum of 8,550 K annual income. Company’s last quarter sales were recorded 30,480 K and last quarter income was 5,060 K.
